Objectives: Severe pneumonia may evoke acute lung injury, and sphingosine-1-phosphate is involved in the regulation of vascular permeability and immune responses. However, the role of sphingosine-1-phosphate and the sphingosine-1-phosphate producing sphingosine kinase 1 in pneumonia remains elusive. We examined the role of the sphingosine-1-phosphate system in regulating pulmonary vascular barrier function in bacterial pneumonia. Design: Controlled, in vitro, ex vivo, and in vivo laboratory study. A full list of board members and other members of the CAPNETZ study group can be viewed in Appendix 1.
; Martin Witzenrath, MD 1, 13 macrophages and human pulmonary microvascular endothelial cells were infected with S. pneumoniae. Transcellular electrical resistance of human pulmonary microvascular endothelial cell monolayers was examined. Further, permeability of murine isolated perfused lungs was determined following exposition to sphingosine-1-phosphate and pneumolysin. Measurements and Main Results: Following S. pneumoniae infection, murine pulmonary sphingosine-1-phosphate levels and sphingosine kinase 1 and sphingosine-1-phosphate receptor 2 expression were increased. Pneumonia-induced lung hyperpermeability was reduced in SphK1 -/-mice compared with wildtype mice. Expression of sphingosine kinase 1 in macrophages recruited to inflamed lung areas in pneumonia was observed in murine and human lungs. S. pneumoniae induced the sphingosine kinase 1/sphingosine-1-phosphate system in blood-derived macrophages and enhanced sphingosine-1-phosphate receptor 2 expression in human pulmonary microvascular endothelial cell in vitro. In isolated mouse lungs, pneumolysin-induced hyperpermeability was dose dependently and synergistically increased by sphingosine-1-phosphate. This sphingosine-1-phosphateinduced increase was reduced by inhibition of sphingosine-1-phosphate receptor 2 or its downstream effector Rho-kinase. Conclusions: Our data suggest that targeting the sphingosine kinase 1-/sphingosine-1-phosphate-/sphingosine-1-phosphate receptor 2-signaling pathway in the lung may provide a novel therapeutic perspective in pneumococcal pneumonia for prevention of acute lung injury. (Crit Care Med 2018; 46:e258-e267) Key Words: acute lung injury; pneumococcal pneumonia; sphingosine kinase 1; sphingosine-1-phosphate; sphingosine-1-phosphate receptor 2 C ommunity-acquired pneumonia (CAP) is a significant cause of morbidity and mortality worldwide, and Streptococcus pneumoniae is the most prevalent causal pathogen identified in CAP (1-3). Despite antibiotic treatment, pneumonia can evoke disruption of pulmonary barrier integrity resulting in acute lung injury (ALI) (4). Endothelial hyperpermeability in pneumonia may be attributed to direct effects of bacterial virulence factors and to uncontrolled host responses. Pneumolysin, an essential virulence factor of S. pneumoniae, can contribute to the development of ALI in pneumococcal pneumonia (5) . Host factors implemented in the pathogenesis of pneumonia-induced ALI include recruitment and activation of leukocytes, increased release of proinflammatory cytokines, and dysregulation of pulmonary barrier function (6) . Treatment of ALI is mainly supportive and aims at improving pulmonary gas exchange. Specific therapeutic strategies effective in preventing or reversing increased lung permeability could reduce pneumonia lethality. However, lung barrier stabilizing therapies are lacking.
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite involved in the regulation of vascular permeability (7) and immune responses (8, 9) . Under homeostatic conditions, coordinated activities of the biosynthetic sphingosine kinases (SphK1 and SphK2) and the biodegradative enzymes S1P phosphatase 1 (S1PP1), S1PP2, and S1P lyase maintain S1P concentrations in the ranges required for optimal physiologic activities (10, 11) . SphK1 activity and S1P production are increased by many mediators involved in inflammatory responses (12) (13) (14) (15) , and inhibition of SphK1 was shown to have potential antiinflammatory properties (14, 16) . However, the role of the SphK1/S1P system in pneumonia is unknown. S1P acts as an intracellular second messenger, regulates store-operated calcium entry (SOCE) (17) and is an extracellular ligand of five cell surface S1P receptors (S1PR 1 to 5) that are differentially expressed and coupled to various G proteins (18, 19) . Physiologic S1P concentrations (0.5-1 µM) increase microvascular barrier integrity via activation of the Gi-coupled S1PR1 (7, 20, 21) and activation of Rac guanosine triphosphatase (22, 23) . Infusion of S1P or its structural analogue, phosphorylated fingolimod, which binds to S1PR1-5 except S1PR2, reduced lung microvascular leakage in different models of lung injury (24) (25) (26) (27) . However, S1P at higher concentration (> 5 µM) mediates RhoA-dependent barrier disruption through binding of S1PR2 and S1PR3, which couple to G i , G q , and G 12/13 (7, 28, 29) . Thus, compartment-specific exact maintenance of physiologic S1P concentrations and homeostasis of S1PRs and S1P synthesis and degradation seem to be crucial for the preservation of lung endothelial barrier integrity, particularly in inflammatory lung diseases.
In this study, we demonstrate that severe pneumonia in mice is associated with increased pulmonary S1P levels and elevated pulmonary SphK1 and S1PR2 expression. Our data provide evidence for S1P delivery to the lungs by monocytes/ macrophages in pneumonia and for increased SphK1 expression in macrophages in response to S. pneumoniae infection. Thereby locally delivered S1P may increase lung permeability via S1PR2 binding. Furthermore, lung permeability was reduced in SphK1-deficient mice with pneumococcal pneumonia, and S1P reconstituted barrier disintegrity via S1PR2.
MATERIALS AND METHODS
Detailed method descriptions are provided in the online supplement (Supplemental Digital Content 1, http://links.lww. com/CCM/D150).
In Vivo Mouse Model of Pneumonia
All animal procedures were approved by institutional and governmental (LAGeSo Berlin) authorities. To reduce interindividual variation caused by using different sex and age, we performed analyses in vivo using 8-10 weeks old female wild-type (C57BL/6N) and SphK1-deficient mice (30) . Anesthetized mice were transnasally inoculated with 5 × 10 6 cfu S. pneumoniae serotype 3 (PN36, NCTC7978) in 20 μL phosphate-buffered saline (5) . For quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), lungs from wild-type mice (Charles River, Sulzfeld, Germany) were processed 12, 24, or 48 hours after infection (p.i.), and S1P levels in wild-type lungs were quantified 24 hours p.i. For histologic investigation, wild-type mice were prepared 48 hours p.i., and the lungs immediately fixed in 4% formalin (31) .
To determine the influence of S1P on lung microvascular leakage in vivo, 6 or 30 hours p.i.
SphK1
-/-and wildtype mice were intraperitoneally injected with S1P (1 mg/kg bodyweight; Sigma-Aldrich, Steinheim, Germany) or solvent (0.9% NaCl). Human serum albumin (HSA) was IV infused 47 hours p.i., and bronchoalveolar lavage fluid (BALF) was collected 48 hours p.i. to determine the HSA BALF/serum ratio (5, 32) .
Immunohistochemical Staining of Mouse Lung Tissue and Human Postmortem Harvested Lungs
For immunohistochemical detection of SphK1 and CD68, mouse and human lungs were fixed in 4% buffered formalin or 3% formalin/63% ethanol, respectively, and processed as described (33) . Antigen retrieval was performed by microwave heating in 10 mM citric acid, pH 6.0 for 12 minutes at 600 W.
For the detection of SphK1, murine and human lung slides were incubated with a primary anti-SphK1 antibody (Abcam, Cambridge, United Kingdom) at 4°C overnight. Subsequently, murine lung slides were incubated with a peroxidase-coupled polymer, attached to a secondary goat antirabbit immunoglobulin G (IgG) antibody (Vector, Burlingame, CA) for 30 minutes at room temperature. For human samples, slides were incubated with biotinylated, secondary goat antirabbit IgG (1:200, BA1000; Vector) antibody and horseradish peroxidase-coupled streptavidin (ABC-HRP Kit, PK-6100; Vector Laboratories, Burlingame, CA).
For the detection of CD68 in human and murine lungs, human lung slides were incubated with a purified mouse antibody polyclonal to CD68 (Abcam, Cambridge, United Kingdom), and murine lung slides were incubated with a purified rabbit antibody, polyclonal to CD68 (Abcam) at 4°C overnight. As secondary antibody, a goat antimouse IgG antibody (Vector) or goat antirabbit IgG antibody was used, and HRP-coupled streptavidin was used.
Diaminobenzidine was used as substrate for color development. All slides were counterstained with hematoxylin, dehydrated through graded ethanol, cleared in xylene, and coverslipped.
Samples from human lungs were obtained postmortem from corpses of body donors at the Institute of Anatomy and Cell Biology, Justus-Liebig University, Giessen, Germany (ethics committee approval ID: 129/14).
Human Blood Monocyte-Derived Macrophage Culture
Monocytes were isolated from donor buffy coats via incubation with anti-CD14 magnetic microbeads (Miltenyi, Bergisch-Gladbach, Germany) and cultured. In vitro differentiated blood-derived macrophages were treated with the specific SphK1 inhibitor 5c (Cay10621; Cayman, Ann Arbor, MI) (34) prior to infection with S. pneumoniae (NCTC 7466; 1 × 10 5 cfu/mL). Cell lysates and supernatants were prepared for SphK1 messenger RNA (mRNA) measurement and S1P quantification, respectively.
Isolated Perfused and Ventilated Mouse Lung
Mice lungs were prepared as described (35) . Lungs were perfused with S1PR2 inhibitor JTE 013 (Tocris Bioscience, Bristol, United Kingdom), Rho-kinase inhibitor Y-27632 (Calbiochem, Bad Soden, Germany) or solvent, and/or S1P. HSA was admixed to perfusion buffer for permeability quantification. Pneumolysin was infused, BAL performed, and HSA concentration determined (36) .
Transcellular Electrical Resistance and Pneumococcal Infection of Endothelial Cells
Human pulmonary microvascular endothelial cells (hu PMVECs; Promocell, Heidelberg, Germany) were grown to confluence on evaporated gold microelectrodes (ibidi, Martinsried, Germany) connected to an electric cell-substrate impedance system (Applied Biophysics, Troy, NY) as described (37, 38) . Cells were exposed to pneumolysin or thrombin alone or simultaneously with S1P, and transcellular electrical resistance (TER) was measured. For infection experiments, huPMVECs were grown to confluence in 12-well cell culture plates and infected with 1 × 10 5 or 5 × 10 5 cfu/mL wild-type S. pneumoniae (serotype 2 D39, NCTC 7466) or pneumolysin-deficient bacteria (serotype 2 D39 pneumolysin deficient strain, AC409). For RNA isolation, cells were lysed in trizol 24 hours p.i., and real-time qRT-PCR was performed to quantify S1PRs.
Data Analysis
Data are expressed as mean + sem. Groups were compared using one-way analysis of variance followed by Newman-Keuls post test (Figs. 1B, 2D , and 3, A and C). 
RESULTS

Levels of S1P and SphK1 mRNA in Murine Lungs
Were Increased p.i. With S. pneumoniae C57BL/6N mice infected with S. pneumoniae had significantly increased S1P levels in lung tissue compared with shaminfected mice 24 hours p.i. (Fig. 1A) . In line with this, relative mRNA expression levels of SphK1 were significantly elevated in murine lung tissue 12 hours p.i., and further increased 48 hours p.i., whereas SphK2, S1PP1, and S1PP2 expressions were not significantly altered in response to infection (Fig. 1B) . Strong SphK1-immunolabeling was seen in macrophages in infected mouse lungs (Fig. 1C) and in postmortem human lungs both in pneumonia while only weak and scattered immunolabeling was seen in unaffected controls (Fig. 2, A and B) . CD68 staining on serial human and murine lung tissue sections confirmed SphK1 expression in macrophages.
Critical Care Medicine www.ccmjournal.org e261 S. pneumoniae Induced SphK1 Expression and S1P Production in Human Blood Monocyte-Derived Macrophages To investigate the specific effect of pneumococcal infection on the SphK1/S1P system in macrophages, human blood monocytes were differentiated into blood-derived macrophages, and SphK1 and S1P were determined 24 hours after pneumococcal infection. S. pneumoniae increased mRNA expression of SphK1 in blood monocyte-derived macrophages (Fig. 2C) . Furthermore, increased S1P levels were detected in the cell culture supernatant p.i. (Fig. 2D ). Inhibiting SphK1 with the specific SphK1 inhibitor 5c (34) reduced S1P levels in supernatant of infected blood monocyte-derived macrophages (Fig. 2D) .
SphK1 Deficiency Reduced, and S1P Enhanced Lung Permeability in Pneumococcal Pneumonia and in Isolated Perfused Mouse Lungs Stimulated With Pneumolysin
To examine the impact of SphK1 and S1P on lung barrier integrity in pneumococcal pneumonia in vivo, lung permeability was quantified 48 hours after S. pneumoniae infection in mice. Permeability was reduced by approximately 60% in SphK1 -/-mice as compared to wild-type mice. Intraperitoneal injection of S1P 6 and 30 hours p.i. reconstituted the permeability increase in SphK1 -/-mice (Fig. 4A) . In isolated perfused and ventilated mouse lungs (IPMLs), infusion of pneumolysin increased lung permeability in a Figure 1 . Streptococcus pneumoniae evoked elevated sphingosine-1-phosphate (S1P) levels and increased sphingosine kinase (SphK) 1 expression in murine lung macrophages. In lungs of mice (n = 7) with and without pneumonia, S1P was quantified 24 hr after infection (A) and messenger RNA (mRNA) expression of S1P-producing and S1P-degrading enzymes was analyzed (n = 4-6 per group) at indicated time points (B). mRNA expression levels were normalized to HPRT levels and ΔCT values were subtracted from 50. C, Immunolocalization of SphK1 in lungs of S. pneumoniae-infected mice revealed strong labeling of macrophages (arrows). Values are given as mean + sem; *p < 0.05; ***p < 0.001 between indicated groups. Bar in C, 100 μm. ΔCT = delta threshold cycle, HPRT = hypoxanthine phosphoribosyl transferase-encoding gene, S1PP = S1P phosphatase.
dose dependent fashion (5, 39, 40) . Whereas S1P infusion (1 μM) did not alter permeability in isolated lungs unexposed to pneumolysin, S1P (1 μM) amplified pneumolysin-induced hyperpermeability in wild-type lungs (Fig. 4B ) but did not influence pulmonary arterial pressure (Fig. S1 , Supplemental Digital Content 2, http://links.lww.com/CCM/D151). In lungs of SphK1 -/-mice, the extend of pneumolysin-induced permeability was comparable to wild-type lungs, and S1P amplified permeability by trend (Fig. S2 , Supplemental Digital Content 3, http://links.lww.com/CCM/D152).
Of note, S1P did not impede disruption of barrier integrity of huPMVECs induced by 1 µg/mL pneumolysin as shown by Figure 2 . Streptococcus pneumoniae (S.pn.) increased sphingosine kinase 1 (SphK1)/sphingosine-1-phosphate (S1P) expression in human macrophages. A-B, Immunolocalization of SphK1 in human lung tissue with pneumonia and in unaffected control tissue revealed strong labeling of macrophages (arrows). In contrast, neutrophil granulocytes showed no SphK1 expression. The CD68 staining on serial human lung tissue sections confirmed SphK1 expression in macrophages. C, SphK1 mRNA levels in S.pn.-infected and noninfected human blood monocyte-derived macrophages were quantified 24 hr after infection, normalized to glyceraldehyde-3-phosphate dehydrogenase levels and compared with SphK1 expression in noninfected cells using the comparative CT method (2 -ΔΔCT method; normalized to the "no infection" group). D, S1P levels in cell culture supernatant from S.pn.-infected monocyte-derived macrophages with or without pretreatment with the specific SphK1 inhibitor 5c or from noninfected cells were measured. Values are given as mean + sem; n = 4-7 per group. *p < 0.05 between indicated groups. Bar in A, 100 μm; bar in B, 50 μm.
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The S1PR2 is Involved in the Synergistic S1P Effect on Pneumolysin-Induced Lung Permeability
In murine pneumonia, pulmonary mRNA expression of S1PR2 peaked 24 hours p.i., while infection had no measurable effect on the expression of S1PR1 and S1PR3 (Fig. 3A) .
Similar to lungs, S1PR2 expression in huPMVECs was increased 24 hours p.i. with S. pneumoniae (1 × 10 5 or 5 × 10 5 cfu/mL), which was not observed p.i. with a pneumolysin-deficient mutant (5 × 10 5 cfu/mL) (Fig. 3B) . Of note, in separate experiments, cells were stimulated with recombinant pneumolysin and 8 hours thereafter S1PR2 mRNA was up-regulated (Fig.  S4 , Supplemental Digital Content 5, http://links.lww. com/CCM/D154). To further study the role of S1PR2 in pneumococcal pneumonia, we analyzed its contribution to S1P enhancement of pneumolysin-induced permeability in isolated lungs. For this purpose, the S1PR2 antagonist JTE 013 was used, or the downstream signaling of S1PR2 via Rho-kinase was inhibited by the Rho-kinase inhibitor Y-27632. Blocking of S1PR2 and inhibition of Rhokinase drastically reduced the permeability enhancing effect of S1P (Fig. 3C) .
DISCUSSION
This study demonstrates that dysregulation of local pulmonary S1P homeostasis in severe pneumonia may contribute to pulmonary vascular barrier dysfunction and the development of ALI. The data show that S1P concentration and SphK1 mRNA in murine lung tissue were increased in pneumococcal pneumonia. Further, expression of SphK1 in macrophages recruited to inflamed lung areas in pneumonia was observed in murine and human lungs. SphK1 expression was enhanced in human blood monocyte-derived macrophages upon infection with S. pneumoniae, promoting liberation of S1P, which increased pneumolysin-induced lung permeability possibly via S1PR2 ligation with subsequent Rho-kinase activation. Thus, inflammation was linked to lung barrier dysfunction by S1P production, S1PR2 induction, and S1PR2 activation.
Previous in vitro data suggested that the basal intrinsic catalytic activity of SphK1 is a critical determinant of the impermeable nature of the endothelium (41) . Further, mutant mice engineered to selectively lack S1P in plasma displayed increased vascular leakage and impaired survival after administration of platelet-activating factor (42) , and numerous reports have suggested protection against increase in vascular permeability by Figure 3 . The sphingosine-1-phosphate receptor (S1PR) 2 is involved in the synergistic sphingosine-1-phosphate (S1P) effect on pneumolysin (PLY)-induced lung permeability. A, Streptococcus pneumoniae induced S1PR2 messenger RNA (mRNA) expression in mice lungs (n = 4-6 per group) at indicated time points, whereas S1PR1 and S1PR3 expressions were not altered. The real-time quantitative reverse transcriptase-polymerase chain reaction data were normalized by subtracting the threshold cycle (CT) levels between the genes of interest and hypoxanthine phosphoribosyl transferase-encoding gene and the ΔCT values were subtracted from 50. B, Increased S1PR2 mRNA expression was also detected in human pulmonary microvascular endothelial cells (huPMVECs) 24 hr after S. pneumoniae infection (1 × 10 5 = 1 × 10 5 cfu/mL). The signal of S1PR1-3 was normalized to GAPDH, and relative expression was calculated by using the comparative CT method (2 -ΔΔCT method; normalized to the "no infection" group). C, Isolated perfused and ventilated lungs of wild-type mice were exposed to intravascular PLY and/or S1P for 30 min as indicated, and lung vascular permeability was assessed by quantifying continuously infused 0.04% human serum albumin (HSA) in bronchoalveolar lavage fluid (BALF) subsequently. Lungs were continuously perfused with S1PR2 antagonist JTE 013 (1 µM), Rho-kinase inhibitor Y-27632 (5 µM), solvent, and/or S1P starting 10 min prior to PLY exposition. Values are given as mean + sem; n = 4-6 (A) or 5-8 (B, C) per group. *p < 0.05; **p < 0.01; ***p < 0.001 between indicated groups. ΔCT = delta threshold cycle, ΔPLY = PLY deficient strain, GAPDH = glyceraldehyde-3-phosphate dehydrogenase, HPRT = hypoxanthine phosphoribosyl transferase-encoding gene.
exogenous S1P via S1PR1 activation (7) . The role of pulmonary S1P and SphK1 under direct inflammatory conditions, however, seems to be more complex, as recent reports have suggested beneficial effects of SphK1 inhibition for vascular barrier integrity in inflammation (43, 44) . Human lung microvascular endothelial cells pretreated with the SphK1 inhibitors sphingosine kinases 1 inhibitor 2 or N,N-dimethylsphingosine showed decreased permeability when exposed to activated neutrophils (43) . In the same study, SKI-2 also inhibited thrombin-induced activation of human pulmonary artery endothelial cells (43) . Along the same line, Lee et al (44) observed that treatment with SKI-2 decreased neutrophils activation and lung permeability in a rat trauma/hemorrhagic shock model. During pneumonia, bacterial recognition by pattern recognition receptors initiates inflammatory signaling pathways evoking secretion of proinflammatory mediators. The innate immune response promotes elimination of bacteria. However, excessive production of proinflammatory mediators may result in tissue damage and vascular leakage. SphK1 plays a key role in inflammatory responses toward several of these proinflammatory mediators, including tumor necrosis factor-α (TNFα), anaphylatoxin C5a, and immune complexes (12) (13) (14) (15) . Notably, SphK1 has recently been reported to be up-regulated in lungs upon lipopolysaccharide-induced ALI in mice (45) and to be important for inflammatory cytokine production in phagocytes of sepsis patients (16) . Furthermore, TNFα-induced neutrophil adhesion occurs via SphK1-dependent activation of endothelial α5β1 integrin (15). Puneet et al (16) observed increased SphK1 activity in peritoneal phagocytes of septic patients, and SphK1 inhibition reduced lung inflammation and improved survival in mouse models of sepsis. Thus, inhibition of SphK1 has been suggested as potential sepsis therapy (16, 46) . However, the role of SphK1 in pneumococcal pneumonia and specifically in endothelial barrier function remains undetermined. Here, we observed up-regulated SphK1 expression in lung tissue of mice upon infection with S. pneumoniae. In line, S1P was increased in mouse lung tissue with pneumonia. In an ex vivo human lung model with lack of cell recruitment, we observed no changes in SphK1 expression and a reduced S1P protein level 18 hours p.i. (Fig.  S5, A and B , Supplemental Digital Content 6, http:// links.lww.com/CCM/D155). We therefore hypothesized that recruited immune cells majorly contribute to increased SphK1 expression in pneumonia. Histologic analyses revealed strong expression of SphK1 in macrophages recruited to lung infiltrates in lungs of mice and in postmortem human lungs with pneumonia supporting our hypothesis. Accordingly, in our study, SphK1 expression and S1P production were induced in human blood-derived macrophages by S. pneumoniae. Furthermore, inhibiting SphK1 with the specific SphK1 inhibitor 5c (16) suggested that SphK1 was required to produce S1P.
To further elucidate the role of SphK1 in regulating lung permeability in pneumococcal pneumonia, we used SphK1 -/-mice. Importantly, lung permeability in pneumonia was significantly reduced in SphK1 -/-mice as compared to wild-type mice. Exogenous S1P reconstituted barrier disruption, suggesting that SphK1 deficiency was beneficial in pneumonia due to reduced S1P production. These results are in agreement with previous studies which emphasized the critical role of SphK1 in regulating inflammatory responses (14, 16, 47) and suggested that inhibition of SphK1 may be a potential therapeutic approach in pneumonia for blocking excessive inflammation and subsequent barrier failure. Of note, in ex vivo perfused lungs lacking cell recruitment, pneumolysin-induced permeability was comparable between wild-type ( Fig. 4B) and SphK1 -/-mice (Fig. S2 , Supplemental Digital Content 3, http://links.lww.com/CCM/ D152). This finding further supports that recruited cells majorily contribute to SphK1, S1P production and consequently permeability increase in lungs with pneumococcal pneumonia. At lower concentrations, S1P is known to enhance integrity of endothelial monolayers and to increase cortical actin in endothelial cells (22) . Accordingly, by quantifying TER of huPMVECs, we observed improved endothelial barrier function -/-as compared to wild-type mice, and intraperitoneal application of S1P 6 hr and 30 hr p.i. reconstituted development of barrier disintegrity in SphK1 -/-mice. Intraperitoneal S1P treatment did not alter lung permeability in uninfected wild-type or SphK1 -/-mice. B, Isolated perfused and ventilated lungs of wild-type mice were exposed to intravascular PLY and/or S1P for 30 min as indicated, and lung vascular permeability was assessed by quantifying continuously infused 0.04% HSA in BALF subsequently. S1P synergistically increased PLY-induced pulmonary hyperpermeability. Values are given as mean + sem; n = 5-9 (A) or 5-8 (B) each group. *p < 0.05; **p < 0.01 between indicated groups.
Critical Care Medicine www.ccmjournal.org e265 after administration of 1 µM S1P. Furthermore, S1P treatment reduced thrombin-evoked permeability by trend which is in line with previous observations (23) . S1P may induce permeability by endoplasmic calcium release and SOCE (17) . We observed that S1P increased [Ca 2+ ]i, and gadolinium (Gd 3+ ) abolished this effect (Fig. S6 , Supplemental Digital Content 7, http://links.lww.com/CCM/D156). Although neither the calcium influx nor its inhibition by Gd 3+ is necessarily specific for SOCE, this observation is consistent with the activation of SOCE by S1P. Interestingly, pneumolysin-evoked endothelial cell permeability was not reduced by S1P. The pneumococcal virulence factor pneumolysin is an intracellular 53-kD protein, which belongs to the family of cholesterol-binding cytolysins and is highly cytotoxic toward target cells due to its pore-forming activities (reviewed in [48] ). To analyze further the interplay of S1P and pneumolysin, IPMLs were exposed to pneumolysin. Administration of 1 µM S1P alone did not significantly alter lung permeability in IPML, and pneumolysin increased lung permeability as expected (5, 39, 40) . Importantly, simultaneous administration of S1P and pneumolysin synergistically increased lung permeability.
Induction of vascular permeability by S1PR2 and its downstream effector Rho-kinase upon S1P ligation has been described (49) , and S1PR2 inhibition by JTE 013 reduced anaphylaxis-induced lung edema (50) . The balance of S1PR1 and S1PR2 receptors is probably critical in determining the effects of S1P on the regulation of endothelial cell permeability and the maintenance of vascular homeostasis (49) . Of note, we found increased pulmonary S1PR2 mRNA expression levels in murine pneumonia and in endothelial cells infected with pneumococci, whereas expression of barrier-enhancing S1PR1 and S1PR3 was unaltered. Infecting endothelial cells with a pneumolysindeficient pneumococcal strain did not affect S1PR2 expression. Further, up-regulation of S1PR2 expression after pneumolysin stimulation suggested involvement of pneumolysin in regulation of endothelial S1PR2 expression. Further, the permeability-increasing properties of S1P in pneumolysintreated IPML were almost completely abolished by chemical inhibition of S1PR2 or Rho-Kinase. These data together suggest that S1PR2 has a major functional role in S1P-evoked deterioration of endothelial barrier integrity in pneumococcal pneumonia.
In conclusion (Fig. 5) , S1P levels and SphK1 mRNA expression in lung tissue were increased in murine pneumonia probably due to SphK1-carrying recruited exudate macrophages. In human blood-derived macrophages, SphK1 expression and S1P production were increased by S. pneumoniae. Lung permeability was reduced in SphK1 -/-mice with pneumococcal pneumonia as compared to wild-type mice, and S1P enhanced pneumolysininduced lung hyperpermeability via activation of endothelial S1PR2, which was increasingly expressed in pneumonia. Thus, in order to improve pulmonary vascular barrier function and prevent development of ALI in severe pneumococcal pneumonia, targeting of S1PR2 ligation by S1P in the lung may provide a novel therapeutic perspective. Conversely, administration of S1P analogues based on their barrier-enhancing properties observed in other context may be contraindicated.
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